Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.710 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript 
Via The Motley Fool
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates
Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance. 
Via Chartmill
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For November 6, 2025
 
Via Benzinga
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Earnings Outlook For Xeris Biopharma Holdings
 
Via Benzinga
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris (XERS) Q2 Revenue Jumps 49%
Via The Motley Fool
Traders are paying attention to the gapping stocks in Thursday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance
Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to... 
Via Chartmill
Topics Earnings
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria
XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score. 
Via Chartmill
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Details for Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template
XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors. 
Via Chartmill
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick?
Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS). 
Via Chartmill
Xeris Announces Changes to Its Board of Directors
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma - Possibly The Best Pharma Stock
The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies. 
Via Talk Markets
Topics Stocks / Equities
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In
The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected. 
Via Stocktwits
These stocks are gapping in today's session
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For March 6, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.